Erik H Niks

List of Publications by Year in Descending Order

83 papers	3,259 citations	33 h-index	56 g-index
97 ext. papers	3,958 ext. citations	5.1 avg, IF	4.81 L-index

#	Paper	IF	Citations
83	Baseline fat fraction is a strong predictor of disease progression in Becker muscular dystrophy.. *NMR in Biomedicine*, **2022**, e4691	4.4	0
82	Low dystrophin variability between muscles and stable expression over time in Becker muscular dystrophy using capillary Western immunoassay. *Scientific Reports*, **2021**, 11, 5952	4.9	3
81	Preserved thenar muscles in non-ambulant Duchenne muscular dystrophy patients. *Journal of Cachexia, Sarcopenia and Muscle*, **2021**, 12, 694-703	10.3	1
80	North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up. *PLoS ONE*, **2021**, 16, e0253882	3.7	1
79	Selection Approach to Identify the Optimal Biomarker Using Quantitative Muscle MRI and Functional Assessments in Becker Muscular Dystrophy. *Neurology*, **2021**, 97, e513-e522	6.5	4
78	Compliance to DMD Care Considerations in the Netherlands. *Journal of Neuromuscular Diseases*, **2021**, 8, 927-938	5	
77	Muscle architecture is associated with muscle fat replacement in Duchenne and Becker muscular dystrophies. *Muscle and Nerve*, **2021**, 64, 576-584	3.4	1
76	Association of Elbow Flexor MRI Fat Fraction With Loss of Hand-to-Mouth Movement in Patients With Duchenne Muscular Dystrophy. *Neurology*, **2021**, 97, e1737-e1742	6.5	0
75	Occurrence of symptoms in different stages of Duchenne muscular dystrophy and their impact on social participation. *Muscle and Nerve*, **2021**, 64, 701-709	3.4	3
74	Resting-state functional MRI shows altered default-mode network functional connectivity in Duchenne muscular dystrophy patients. *Brain Imaging and Behavior*, **2021**, 15, 2297-2307	4.1	1
73	Characterization of patients with Becker muscular dystrophy by histology, magnetic resonance imaging, function, and strength assessments.. *Muscle and Nerve*, **2021**,	3.4	2
72	Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy. *Journal of Neuromuscular Diseases*, **2020**, 7, 231-246	5	8
71	MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy. *Neurology*, **2020**, 94, e1386-e1394	6.5	27
70	242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019. *Neuromuscular Disorders*, **2020**, 30, 254-264	2.9	6
69	Normalized grip strength is a sensitive outcome measure through all stages of Duchenne muscular dystrophy. *Journal of Neurology*, **2020**, 267, 2022-2028	5.5	7
68	Decision-Making And Selection Bias in Four Observational Studies on Duchenne and Becker Muscular Dystrophy. *Journal of Neuromuscular Diseases*, **2020**, 7, 433-442	5	3
67	Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy. *Journal of Cachexia, Sarcopenia and Muscle* , **2020**, 11, 505-517	10.3	14

66	TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy. *European Journal of Human Genetics*, **2020**, 28, 815-825	5.3	10
65	Multi-parametric MR in Becker muscular dystrophy patients. *NMR in Biomedicine*, **2020**, 33, e4385	4.4	8
64	Rotavirus-Induced Neonatal Epileptic Encephalopathy-A Disease Spectrum Illustrated by Monochorionic Twins. *Neuropediatrics*, **2020**, 51, 62-67	1.6	3
63	T relaxation-time mapping in healthy and diseased skeletal muscle using extended phase graph algorithms. *Magnetic Resonance in Medicine*, **2020**, 84, 2656-2670	4.4	13
62	Autosomal recessive limb-girdle and Miyoshi muscular dystrophies in the Netherlands: The clinical and molecular spectrum of 244 patients. *Clinical Genetics*, **2019**, 96, 126-133	4	16
61	Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study. *Neuromuscular Disorders*, **2019**, 29, 261-268	2.9	19
60	The landscape of epilepsy-related GATOR1 variants. *Genetics in Medicine*, **2019**, 21, 398-408	8.1	75
59	Muscle biopsies in clinical trials for Duchenne muscular dystrophy - PatientsU and caregiversU perspective. *Neuromuscular Disorders*, **2019**, 29, 576-584	2.9	11
58	Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. *Journal of Cachexia, Sarcopenia and Muscle*, **2018**, 9, 715-726	10.3	32
57	Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice. *Neuromuscular Disorders*, **2018**, 28, 427-442	2.9	9
56	Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies. *Annals of the New York Academy of Sciences*, **2018**, 1413, 111-118	6.5	2
55	Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study. *Journal of Neurology*, **2018**, 265, 1310-1319	5.5	32
54	Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients. *Epigenomics*, **2018**, 10, 875-889	4.4	15
53	Improved olefinic fat suppression in skeletal muscle DTI using a magnitude-based dixon method. *Magnetic Resonance in Medicine*, **2018**, 79, 152-159	4.4	22
52	Non-uniform muscle fat replacement along the proximodistal axis in Duchenne muscular dystrophy. *Neuromuscular Disorders*, **2017**, 27, 458-464	2.9	39
51	Proton Magnetic Resonance Spectroscopy Indicates Preserved Cerebral Biochemical Composition in Duchenne Muscular Dystrophy Patients. *Journal of Neuromuscular Diseases*, **2017**, 4, 53-58	5	3
50	Elevated phosphodiester and T levels can be measured in the absence of fat infiltration in Duchenne muscular dystrophy patients. *NMR in Biomedicine*, **2017**, 30, e3667	4.4	31
49	Exon skipping: a first in class strategy for Duchenne muscular dystrophy. *Expert Opinion on Biological Therapy*, **2017**, 17, 225-236	5.4	75

48	Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy. *Scientific Reports*, **2017**, 7, 12575	4.9	70
47	Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis. *Journal of Neuromuscular Diseases*, **2017**, 4, 327-335	5	5
46	Decreased cerebral perfusion in Duchenne muscular dystrophy patients. *Neuromuscular Disorders*, **2017**, 27, 29-37	2.9	16
45	Prevalence and clinical aspects of immigrants with myasthenia gravis in northern Europe. *Muscle and Nerve*, **2017**, 55, 819-827	3.4	9
44	PO195 Outcome measures for duchenne muscular dystrophy: implications for trials. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, A63.1-A63	5.5	
43	Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne. *Scientific Reports*, **2017**, 7, 17888	4.9	10
42	Spatially localized phosphorous metabolism of skeletal muscle in Duchenne muscular dystrophy patients: 24-month follow-up. *PLoS ONE*, **2017**, 12, e0182086	3.7	20
41	Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models. *European Journal of Neuroscience*, **2016**, 43, 1623-35	3.5	44
40	Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. *Lancet Neurology, The*, **2016**, 15, 882-890	24.1	58
39	Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. *Journal of Neuroimmunology*, **2016**, 291, 82-8	3.5	37
38	Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis. *Neuromuscular Disorders*, **2016**, 26, 350-3	2.9	17
37	Diagnosis and treatment of obsessive compulsive behavior in a boy with Duchenne muscular dystrophy and autism spectrum disorder: A case report. *Neuromuscular Disorders*, **2016**, 26, 659-661	2.9	6
36	T2 relaxation times are increased in Skeletal muscle of DMD but not BMD patients. *Muscle and Nerve*, **2016**, 53, 38-43	3.4	36
35	Prognostic factors for exacerbations and emergency treatments in myasthenia gravis. *Journal of Neuroimmunology*, **2015**, 282, 123-5	3.5	20
34	An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. *Health and Quality of Life Outcomes*, **2015**, 13, 115	3	38
33	Evaluation of skeletal muscle DTI in patients with duchenne muscular dystrophy. *NMR in Biomedicine*, **2015**, 28, 1589-97	4.4	71
32	The expanding field of IgG4-mediated neurological autoimmune disorders. *European Journal of Neurology*, **2015**, 22, 1151-61	6	105
31	Geographical Distribution of Myasthenia Gravis in Northern Europe--Results from a Population-Based Study from Two Countries. *Neuroepidemiology*, **2015**, 44, 221-31	5.4	23

30	Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy. *Neuromuscular Disorders*, **2014**, 24, 216-21	2.9	16
29	Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling. *Nature Genetics*, **2014**, 46, 188-93	36.3	242
28	Fibronectin is a serum biomarker for Duchenne muscular dystrophy. *Proteomics - Clinical Applications*, **2014**, 8, 269-78	3.1	55
27	Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy. *Neuromuscular Disorders*, **2014**, 24, 409-16	2.9	103
26	Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis. *Journal of Internal Medicine*, **2014**, 275, 12-26	10.8	36
25	Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies. *EMBO Molecular Medicine*, **2014**, 6, 918-36	12	81
24	Reduced cerebral gray matter and altered white matter in boys with Duchenne muscular dystrophy. *Annals of Neurology*, **2014**, 76, 403-11	9.4	59
23	Age-related longitudinal changes in metabolic energy expenditure during walking in boys with Duchenne muscular dystrophy. *PLoS ONE*, **2014**, 9, e115200	3.7	7
22	Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. *Neuromuscular Disorders*, **2013**, 23, 170-5	2.9	43
21	MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 20783-8	11.5	182
20	Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. *Autoimmunity Reviews*, **2013**, 12, 918-23	13.6	110
19	Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome. *Human Immunology*, **2013**, 74, 849-51	2.3	8
18	Sprengelʼs deformity and spinal dysraphism: connecting the shoulder and the spine. *Childʼs Nervous System*, **2013**, 29, 1051-8	1.7	5
17	DOK7 congenital myasthenic syndrome in childhood: early diagnostic clues in 23 children. *Neuromuscular Disorders*, **2013**, 23, 883-91	2.9	28
16	Risk for myasthenia gravis maps to a (151) Pro-Ala change in TNIP1 and to human leukocyte antigen-B*08. *Annals of Neurology*, **2012**, 72, 927-35	9.4	112
15	Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. *Journal of Neurology*, **2012**, 259, 1929-35	5.5	78
14	Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. *Brain*, **2012**, 135, 1081-101	11.2	148
13	IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. *Journal of Proteome Research*, **2011**, 10, 143-52	5.6	70

12	Reduced thymic expression of ErbB receptors without auto-antibodies against synaptic ErbB in myasthenia gravis. *Journal of Neuroimmunology*, **2011**, 232, 158-65	3.5	6
11	Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia. *Muscle and Nerve*, **2010**, 42, 283-8	3.4	45
10	Detecting dysphagia in inclusion body myositis. *Journal of Neurology*, **2009**, 256, 2009-13	5.5	73
9	Herpes simplex virus type-1 encephalitis and occipital ischemic stroke. *Pediatric Neurology*, **2009**, 41, 294-6	2.9	11
8	The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. *American Journal of Pathology*, **2009**, 175, 1536-44	5.8	35
7	Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. *Journal of Neuroimmunology*, **2008**, 195, 151-6	3.5	97
6	A transient neonatal myasthenic syndrome with anti-musk antibodies. *Neurology*, **2008**, 70, 1215-6	6.5	50
5	Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands. *Journal of Neurology, Neurosurgery and Psychiatry*, **2007**, 78, 417-8	5.5	55
4	Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. *American Journal of Pathology*, **2007**, 171, 893-905	5.8	90
3	Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. *Neurology*, **2006**, 66, 1772-4	6.5	100
2	Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. *Annals of Neurology*, **2005**, 57, 444-8	9.4	186
1	Decremental response of the nasalis and hypothenar muscles in myasthenia gravis. *Muscle and Nerve*, **2003**, 28, 236-8	3.4	20